AST's OPC1 cells show durable effect...Seeing Alpha | AST Message Board Posts


Asterias Biotherapeutics, Inc.

  AST website

AST   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  134 of 136  at  1/24/2019 6:18:07 PM  by

Sixty2nds


AST's OPC1 cells show durable effect...Seeing Alpha

Asterias' OPC1 cells show durable effect after a year in spinal cord injury patients

Top-line data at month 12 in a Phase 1/2a clinical trial, SCiStar, evaluating Asterias Biotherapeutics' (NYSEMKT:AST) OPC1 cells in patients with severe spinal cord injuries showed a sustained effect.
MRI scans a year after injection showed no evidence of adverse changes in any of the 25 treated patients.
MRI scans from three subjects in Cohort 1 and 95% (n=21/22) in Cohorts 2-5 were consistent with tissue matrix formation at the injury site.
95% (n=21/22) of patients receiving either 10M or 20M cells recovered at least one motor level on at least one side. 32% (n=7/22) recovered at least two levels on at least one side.
A Phase 2 trial is next up.
| Today, 8:03 AM | 10 Comments


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 183 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...